



## Tauopathies: New Perspectives and Challenges

Guest Editors:

**Dr. Kathryn Bowles**

UK Dementia Research Institute,  
University of Edinburgh,  
Edinburgh EH16 4SB, UK

**Dr. Maria Catarina Silva**

1. Center for Genomic Medicine,  
Chemical Neurobiology  
Laboratory, Department of  
Neurology, Massachusetts  
General Hospital, Boston, MA  
02114, USA  
2. Department of Neurology,  
Harvard Medical School, Boston,  
MA 02115, USA

Deadline for manuscript  
submissions:

**closed (31 March 2024)**

### Message from the Guest Editors

Tauopathies are a fascinating and vast assembly of neurodegenerative diseases, spanning multiple distinct neuropathological features, cellular phenotypes and clinical presentations. This diversity and complexity make tauopathies particularly challenging to model. Regardless, recent advancements in animal and cellular models have accelerated our knowledge and understanding of these diseases. In parallel, the development and application of new technologies to study and characterize these models have expanded our horizons for what is possible to know. However, we still have a long way to go with regard to untangling the complexity and pleiotropy of *MAPT*, tau and tauopathies, and developing effective therapies and treatments.

We invite authors from any area of the tauopathy field to submit original research or review articles pertaining to this special issue. Studies and opinions on new approaches and technologies that have changed our perspective of the field, where we are currently lacking in our efforts and understanding, and the challenges we face to make meaningful progress are encouraged.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI